News

Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340. Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments. The company

The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years. The company plans to source Phase

The regulatory status specifically includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which the candidate is presently being evaluated. Orphan status is granted to support the

Concurrently, the National Institute for Health and Care Excellence (NICE) has published Technology Appraisal guidance recommending funding for the National Health Service (NHS) for adult patients with genetically

The arrangement builds on a partnership with the Biomedical Advanced Research and Development Authority (BARDA) established in 2020. BARDA is part of the Administration for Strategic Preparedness and

The submission seeks approval for patients diagnosed with unresectable or metastatic melanoma whose condition has progressed following at least two previous systemic treatments, including anti- programmed death-1 (PD-1)

Under the partnership, the platform will be applied to haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics. The companies plan to utilise the tool to identify

The transaction values the US-based biotechnology company at approximately $3bn post-money. Bristol Myers Squibb (BMS) led the funding round, with further capital provided by existing investors. Pathos AI

The partnership focuses on evaluating digital patient twins, which are computer-based models of individual patients constructed from clinical and related data. The companies intend to examine whether these